Navigation Links
Mayo-led study: Drug fails to reduce diarrhea in patients receiving radiation therapy
Date:9/24/2013

ROCHESTER, Minn. -- Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found. The study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. The results were presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting in Atlanta.

"Patients receiving radiation therapy in the pelvic region can experience diarrhea which is a negative side effect of the therapy," says the study's lead author Robert Miller, M.D., a radiation oncologist at Mayo Clinic. Dr. Miller says that in previous trials sulfasalazine, which treats bowel inflammation, had been shown to decrease diarrhea in patients during pelvic radiation therapy.

Dr. Miller led a two-year, randomized, double-blind, placebo-controlled phase III clinical trial through the Alliance for Clinical Trials in Oncology to evaluate the effectiveness of sulfasalazine versus placebo in inflammation of the bowel during pelvic radiation therapy. The trial included 87 patients, with 78 patients evaluated for the primary endpoint, which was maximal severity of diarrhea up to six weeks after therapy, based on commonly accepted criteria. Patients enrolled in the study came from 24 institutions in the United States.

Patients received 1,000 milligrams of sulfasalazine or placebo orally, twice each day during radiation therapy and for four weeks after therapy. Patients completed bowel function questionnaires weekly during therapy, afterward for six weeks and at 12 and 24 months after therapy. Health care providers graded each patient on the maximum severity and the duration of maximum severity of diarrhea, rectal bleeding, abdominal cramping, constipation and tenesmus, the sensation of incomplete defecation.

Interim results from the study found a statistically significant excess of grade 3 diarrhea -- passing seven or more stools per day, in patients receiving sulfasalazine versus placebo. The study was halted in May 2013 when researchers determined that it was unlikely sulfasalazine would show benefit.

"While previous research had suggested benefit for sulfasalazine, we were very surprised to find that patients receiving sulfasalazine experienced worse diarrhea than those receiving placebo," Dr. Miller says. "We now know that sulfasalazine will not help patients receiving radiation therapy in the pelvic region avoid diarrhea as a side effect of the therapy." Dr. Miller says the study illustrates the need for large, phase III, randomized controlled trials to better understand which drugs and therapies can help mitigate the negative side effects for patients receiving radiation therapy.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
504-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Cancer-causing gene alone doesnt trigger pancreatic cancer, Mayo-led study finds
2. Study: Memory problems, emotional stress result in early readmissions of heart patients
3. Study: Redefining the Criteria for ALK Positive Lung Cancer
4. Study: Redefining the criteria for ALK positive lung cancer
5. ACR, SBI on cancer study: More breast cancer screening needed in younger women
6. Study: Disease caused by repeat brain trauma in athletes may affect memory, mood, behavior
7. Study: Many evangelicals are ambivalent about homosexuality and civil unions for gays
8. Study: Heart pump with behind-the-ear power connector
9. Study: Centers throughout the brain work together to make reading possible
10. Study: Taxing sugary beverages not a clear cut strategy to reduce obesity
11. Study: Taxing Sugary Beverages Not a Clear Cut Strategy to Reduce Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: